Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co ElifiledCriticalLilly Co Eli
Publication of CR9572ApublicationCriticalpatent/CR9572A/en
Acyclic And Carbocyclic Compounds In Medicinal Compositions
(AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
La presente invencion se refiere a un regimen de dosificacion para prevencion y/o tratamiento de una enfermedad vascular en un humano, que comprende las etapas de administrar una dosis de carga de aproximadamente 30 mg hasta 70mg de dosis de prasugrel o una sal del mismo farmaceuticamente aceptable, y posteriormente administrar un regimen de dosificacion diariamente de aproximadamente 7.5 mg hasta 15 mg de dosis de mantenimiento de prasugrel o una sal del mismo farmaceuticamente aceptable.The present invention relates to a dosage regimen for prevention and / or treatment of a vascular disease in a human, comprising the steps of administering a loading dose of approximately 30 mg to 70 mg of prasugrel dose or a pharmaceutically salt thereof. acceptable, and then administer a daily dosage regimen of approximately 7.5 mg to 15 mg of maintenance dose of prasugrel or a pharmaceutically acceptable salt thereof.
CR9572A2006-06-132007-12-06
DOSAGE REGIME FOR PRASUGREL
CR9572A
(en)
ORAL DOSAGE FORM OF CONTROLLED RELEASE THAT INCLUDES 4- (2-DI-N-PROPILAMINOETIL) - 2 (3H) -INDOLONE (ROPI-NIROL) AND USE OF SUCH DOSAGE FORM FOR THE PREPARATION OF A MEDICINAL PRODUCT
INHIBITOR OF THE CHOLESTERILE ESTER TRANSFER PROTEIN (CETP) AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE SUCH INHIBITOR FOR USE IN THE TREATMENT OR PREVENTION OF CARDIOVASCULAR DISEASES